Key Takeaways Leadership in AI is increasingly shaped by personal experiences such as parenthood, influencing decisions that prioritise societal impact and ethical development. Empirical studies suggest that fathers in tech...
Key Takeaways Astera Labs reported 150% year-over-year revenue growth in Q2 FY2025, with a Rule of 40 score over 190 and free cash flow margins of approximately 40%. Strategic partnerships...
Key Takeaways Salesforce trades at a forward P/E of 22.3, well below its historical average and competitors in the SaaS sector. Revenue for fiscal 2025 is projected at $38 billion,...
Key Takeaways SentinelOne reported Q1 FY2026 revenue of $229 million, up 23% year-over-year, driven by strong demand for its AI-powered Singularity Platform. Positive free cash flow reached $53.13 million, reflecting...
Key Takeaways Fiserv’s forward P/E of 13.71, significantly below industry averages, suggests potential undervaluation despite strong cash flow predictability. The Clover platform is a critical growth driver, with increasing adoption...
Key Takeaways Zeta Global projects free cash flow of $430–$440 million annually by 2028, supported by a 39% compound annual growth rate. Full-year 2024 revenue reached $1.006 billion, up 38%...
Key Takeaways The Pentagon has maintained restrictions on Ukraine’s use of long-range U.S. missiles against Russian territory, influencing both military strategy and defence-sector demand. Prolonged limitations may contribute to higher...
Key Takeaways LivaNova demonstrated 10.7% year-over-year revenue growth in Q2 2025, outpacing analyst expectations and lifting full-year guidance. Robust performance in both cardiopulmonary (13.1% growth) and neuromodulation (3.8% growth) underscores...
Key Takeaways Vertex Pharmaceuticals holds a dominant 95% share of the US cystic fibrosis (CF) market, fortified by Trikafta’s patent protection through 2037. The CF market is projected to grow...
Key Takeaways PROCEPT BioRobotics’ Aquablation therapy offers a minimally invasive and repeatable alternative for treating benign prostatic hyperplasia (BPH), distinguished by its precision and reduced complication rates. Regulatory milestones—including Category...
